Xencor Narrows Losses by 54% on Soaring Collaboration Revenue

TL;DR

**Xencor's narrowing losses and surging collaboration revenue make it a speculative buy, but watch cash burn closely.**

AI Summary

Xencor Inc. reported a significant increase in revenue from collaborations, milestones, and royalties, reaching $97.339 million for the nine months ended September 30, 2025, up from $57.700 million in the same period of 2024, representing a 68.7% increase. This was primarily driven by a substantial increase in revenue from the Incyte collaboration, which surged from $6.528 million in 2024 to $44.332 million in 2025. Despite this revenue growth, the company recorded a net loss attributable to Xencor Inc. of $85.270 million for the nine months ended September 30, 2025, a considerable improvement from the $187.065 million loss in the prior year, marking a 54.4% reduction. Operating expenses remained relatively stable, with research and development decreasing slightly to $174.610 million from $176.630 million, and general and administrative expenses rising marginally to $46.603 million from $46.300 million. A notable gain on marketable equity securities of $50.109 million for the nine months ended September 30, 2025, compared to a loss of $0.448 million in 2024, significantly offset operating losses. Cash and cash equivalents decreased from $40.875 million at December 31, 2024, to $28.291 million at September 30, 2025, while total assets declined from $951.945 million to $868.811 million over the same period.

Why It Matters

Xencor's substantial reduction in net loss and significant revenue growth from collaborations, particularly with Incyte, signals improved operational efficiency and potential for future profitability, which is crucial for investors in the volatile biotech sector. The company's ability to secure and advance partnerships like Alexion and Incyte demonstrates its competitive edge in protein engineering and drug development, potentially attracting more collaborators and strengthening its market position against rivals. For employees, this financial improvement could mean greater job security and continued investment in R&D, while customers could benefit from accelerated development of new cancer and autoimmune disease treatments. The broader market will watch if Xencor can sustain this positive trajectory and translate its clinical-stage pipeline into commercial success, impacting investor sentiment for similar clinical-stage biopharmaceutical companies.

Risk Assessment

Risk Level: medium — While Xencor significantly reduced its net loss by 54.4% to $85.270 million for the nine months ended September 30, 2025, it still reported a net loss of $6.027 million for the three months ended September 30, 2025. The company's cash and cash equivalents decreased from $40.875 million to $28.291 million, and total current assets fell from $577.601 million to $518.441 million, indicating continued cash usage despite improved revenue.

Analyst Insight

Investors should monitor Xencor's upcoming clinical trial results and further collaboration announcements, as these are critical for sustained revenue growth and eventual profitability. Given the improved financial performance, consider a small, speculative position, but be prepared for continued volatility inherent in clinical-stage biopharmaceutical companies.

Financial Highlights

debt To Equity

N/A

revenue

$97,339,000

operating Margin

N/A

total Assets

$868,811,000

total Debt

N/A

net Income

-$85,270,000

eps

N/A

gross Margin

N/A

cash Position

$28,291,000

revenue Growth

+68.7%

Revenue Breakdown

Key Numbers

• $97.339M — Revenue from collaborations, milestones, and royalties (Increased from $57.700M in 2024 for the nine months ended September 30, 2025)
• $85.270M — Net loss attributable to Xencor Inc. (Reduced from $187.065M in 2024 for the nine months ended September 30, 2025)
• 54.4% — Reduction in net loss (Percentage decrease in net loss attributable to Xencor Inc. year-over-year)
• $50.109M — Gain on marketable equity securities, net (For the nine months ended September 30, 2025, compared to a $0.448M loss in 2024)
• $28.291M — Cash and cash equivalents (As of September 30, 2025, down from $40.875M at December 31, 2024)
• $868.811M — Total assets (As of September 30, 2025, down from $951.945M at December 31, 2024)
• $174.610M — Research and development expenses (For the nine months ended September 30, 2025, a slight decrease from $176.630M in 2024)
• 71,410,469 — Common stock shares outstanding (As of October 30, 2025)

Key Players & Entities

• Xencor Inc. (company) — clinical-stage biopharmaceutical company
• Incyte (company) — collaboration partner
• Alexion (company) — collaboration partner
• Gale Therapeutics Inc. (company) — variable interest entity merged into Xencor
• FASB (regulator) — Financial Accounting Standards Board
• Nasdaq Global Market (regulator) — exchange where XNCR is registered
• SEC (regulator) — Securities and Exchange Commission
• Delaware (regulator) — state of incorporation

FAQ

Risk Factors

• Competition in the Biopharmaceutical Industry [high — market]: Xencor faces significant competition in the biopharmaceutical industry. The success of its product candidates depends on their market acceptance and clinical utility, which are subject to the capabilities and strategies of competitors.
• Regulatory Approval and Compliance [high — regulatory]: The company's ability to obtain and maintain regulatory approvals for its product candidates is critical. Failure to comply with new and existing governmental regulations can lead to significant costs and operational challenges.
• Execution of Research and Development Plans [high — operational]: Xencor's ability to execute its plans to research, develop, and commercialize its product candidates is a key risk. This includes the success of ongoing and planned clinical trials and the ability to identify additional products with commercial potential.
• Inflationary Impact on Financials [medium — financial]: Inflation can affect Xencor's financial condition, results of operations, cash flows, and performance. The company must manage its operations and financial strategies in light of these economic pressures.
• Reliance on Collaborators and Partners [medium — operational]: The success of Xencor's drug candidates is also dependent on its partners' abilities to advance drug candidates through clinical trials and obtain regulatory approvals. Attracting collaborators with necessary expertise is crucial.
• Intellectual Property Protection [medium — operational]: Protecting the company's intellectual property position is vital. Any failure to adequately safeguard its patents and proprietary technologies could negatively impact its competitive advantage.
• Supplier and Vendor Capabilities [medium — operational]: The capabilities and strategies of suppliers and vendors, including key manufacturers of clinical drug supplies, are important. Disruptions or failures in this supply chain could impact development timelines and costs.
• Key Personnel Retention [low — operational]: The potential loss or retirement of key members of management poses a risk to the company's strategic execution and operational continuity.

Industry Context

Xencor operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on engineered antibody therapeutics for cancer and autoimmune diseases. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and strategic partnerships to navigate the path to commercialization.

Regulatory Implications

Xencor faces substantial regulatory hurdles in bringing its drug candidates to market. Obtaining and maintaining approvals from bodies like the FDA is critical. Compliance with evolving governmental regulations is essential to avoid penalties and operational disruptions, impacting the timeline and cost of development.

What Investors Should Do

1. Monitor Incyte Collaboration Performance
2. Analyze Cash Burn Rate and Funding Needs
3. Evaluate the Impact of Marketable Equity Securities Gains
4. Assess Progress in Clinical Trials and Pipeline Development

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported significant revenue growth from collaborations and a reduced net loss, offset by a decrease in cash and total assets.
• 2024-09-30: Nine months ended September 30, 2024 — Prior period for comparison, showing lower revenue and a larger net loss.
• 2025-12-31: As of December 31, 2024 — Previous year-end balance sheet figures for cash and total assets.

Glossary

Marketable equity securities

Investments in the stock of other companies that are readily tradable on public exchanges. (A significant gain on these securities ($50.109 million) helped offset operating losses for the nine months ended September 30, 2025.)

Accumulated deficit

The total net losses of a company since its inception, less any net income. It represents a cumulative negative retained earnings. (Xencor has an accumulated deficit of $789.306 million as of September 30, 2025, indicating it has historically incurred more losses than profits.)

Noncontrolling interest

The portion of equity interest in a subsidiary that is not attributable to the parent company. This was previously recognized by Xencor related to Gale Therapeutics Inc. (Xencor no longer recognizes noncontrolling interest as of January 20, 2025, after obtaining 100% economic interest in Gale.)

XmAb drug candidates

Drug candidates developed by Xencor that leverage its proprietary protein engineering capabilities to create antibody therapeutics with improved properties. (These are the core of Xencor's product pipeline, aimed at treating cancer and autoimmune diseases.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Xencor reported a substantial 68.7% increase in revenue from collaborations, milestones, and royalties, reaching $97.339 million, primarily due to the Incyte collaboration. This revenue growth, coupled with a significant $50.109 million gain on marketable equity securities, helped reduce the net loss attributable to Xencor Inc. by 54.4% to $85.270 million, compared to the prior year. However, cash and cash equivalents saw a notable decrease, falling from $40.875 million at year-end 2024 to $28.291 million as of September 30, 2025, and total assets also declined.

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share XNCR The Nasdaq Global Marke

Filing Documents

• xncr-20250930.htm (10-Q) — 1303KB
• xncr-20250930xexx101.htm (EX-10.1) — 37KB
• xncr-20250930xexx102.htm (EX-10.2) — 86KB
• xncr-20250930xexx311.htm (EX-31.1) — 10KB
• xncr-20250930xexx312.htm (EX-31.2) — 10KB
• xncr-20250930xexx321.htm (EX-32.1) — 6KB
• 0001326732-25-000087.txt ( ) — 7827KB
• xncr-20250930.xsd (EX-101.SCH) — 48KB
• xncr-20250930_cal.xml (EX-101.CAL) — 84KB
• xncr-20250930_def.xml (EX-101.DEF) — 245KB
• xncr-20250930_lab.xml (EX-101.LAB) — 652KB
• xncr-20250930_pre.xml (EX-101.PRE) — 469KB
• xncr-20250930_htm.xml (XML) — 1281KB

Financial Statements

Financial Statements 3 Consolidated Balance Sheets 3 Consolidated Statements of Operations and Comprehensive Loss 4 Consolidated Statements of Stockholders' Equity 5 Consolidated Statements of Cash Flows 6

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION 31 Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Default upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 35 Item 6. Exhibits 35 SIGNATURE 36 In this report, unless otherwise stated or the context otherwise indicates, references to "Xencor," "the Company," "we," "us," "our" and similar references refer to Xencor, Inc. The Xencor logo is a registered trademark of Xencor, Inc. This report also contains registered marks, trademarks, and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders. 1 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology. These forward-looking statements should, therefore, be considered in light of various important factors, including but not limited to, the following: the effects of inflation on our financial condition, results of operations, cash flows and performance; our ability to execute on our plans to research, develop and commercialize our product candidates; the success of our ongoing and planned clinical trials; the timing of and our ability to obtain and maintain regulatory a

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Xencor, Inc. Consolidated Balance Sheets (in thousands, except per share amounts) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 28,291 $ 40,875 Marketable debt securities 358,493 408,971 Marketable equity securities 84,260 47,929 Accounts receivable 21,805 60,849 Prepaid expenses and other current assets 25,592 18,977 Total current assets 518,441 577,601 Property and equipment, net 54,587 59,800 Patents, licenses, and other intangible assets, net 9,468 18,485 Restricted cash 288 387 Marketable debt securities - long term 247,158 256,833 Right-of-use assets 38,371 38,341 Other assets 498 498 Total assets $ 868,811 $ 951,945 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 9,079 $ 16,759 Accrued expenses 28,108 19,217 Lease liabilities 3,936 3,009 Liabilities related to the sales of future royalties 45,362 48,447 Total current liabilities 86,485 87,432 Uncertain tax position payable 3,903 9,990 Lease liabilities, net of current portion 65,331 65,338 Liabilities related to the sales of future royalties, net of current portion 87,776 115,159 Total liabilities 243,495 277,919 Commitments and contingencies Noncontrolling interest and stockholders' equity Common stock, $ 0.01 par value: Authorized 200,000 shares Issued and outstanding 71,343 and 70,256 shares at September 30, 2025 and December 31, 2024, respectively. 714 703 Additional paid-in capital 1,412,750 1,381,607 Accumulated other comprehensive income (loss) 1,158 ( 663 ) Accumulated deficit ( 789,306 ) ( 704,036 ) Total stockholders' equity attributable to Xencor, Inc. 625,316 677,611 Noncontrolling interest — ( 3,585 ) Total noncontrolling interest and stockholders' equity 625,316 674,026 Total liabilities and stockholders' equity $ 868,811 $ 951,945 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (unaudited) 1. Organization and Summary of Significant Accounting Policies Organization Xencor, Inc. (the "Company") was incorporated in California in 1997 and reincorporated in Delaware in September 2004. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. The Company leverages its protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties. These candidates are advanced into clinical-stage development, where the Company is conducting Phase 1 and Phase 2 studies across a broad portfolio of programs. Based on the results of these studies, the Company determines which programs to advance into later-stage development and potential commercialization, which to partner in order to access complementary resources, and which to discontinue. Consolidation and Basis of Presentation The interim consolidated financial statements of Xencor, Inc. are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") applicable to interim periods. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company's financial position, the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain note disclosures that are normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted as they are not required for interim reporting purposes. Readers are urged to review the Company's Annual Report on Form 10-K for the year ended December 31, 2024 for more complete descriptions and discussions. Operating results and cash flows for the three and nine months ended September 30, 2025 are not necessarily

View Full Filing

View this 10-Q filing on SEC EDGAR